Evidence map›Paper›PMID 24826055›Full record

ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2014

Retrospective analysis of results of treatment for nasopharyngeal carcinoma in Macao.

Huiqin Dou, Dongyan Hu, Chileong Lam, Yunsheng Liu, Xiuwen Wang, Wendong Zhang

Open access · greenAbstract read
In one paragraph

Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Arnicolide D, from the herbMolecules (Basel, Switzerland) · 2019
    Article
  9. Article
  10. Synthesis of gold nanoparticles withInternational journal of nanomedicine · 2018
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Huiqin Dou1 Department of Stomatology, 2 Department of Clinical Oncology, Qilu Hospital of Shandong University, Jinan 250012, China ; 3 Department of Clinical Oncology, Conde S. Januario General Hospital, Macao, China.
Dongyan Hu1 Department of Stomatology, 2 Department of Clinical Oncology, Qilu Hospital of Shandong University, Jinan 250012, China ; 3 Department of Clinical Oncology, Conde S. Januario General Hospital, Macao, China.
Chileong Lam1 Department of Stomatology, 2 Department of Clinical Oncology, Qilu Hospital of Shandong University, Jinan 250012, China ; 3 Department of Clinical Oncology, Conde S. Januario General Hospital, Macao, China.
Yunsheng Liu1 Department of Stomatology, 2 Department of Clinical Oncology, Qilu Hospital of Shandong University, Jinan 250012, China ; 3 Department of Clinical Oncology, Conde S. Januario General Hospital, Macao, China.
Xiuwen Wang1 Department of Stomatology, 2 Department of Clinical Oncology, Qilu Hospital of Shandong University, Jinan 250012, China ; 3 Department of Clinical Oncology, Conde S. Januario General Hospital, Macao, China.
Wendong Zhang1 Department of Stomatology, 2 Department of Clinical Oncology, Qilu Hospital of Shandong University, Jinan 250012, China ; 3 Department of Clinical Oncology, Conde S. Januario General Hospital, Macao, China.
Qilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNasopharyngeal carcinoma (NPC) is a common malignancy in Southeast Asia, however, a full consensus has not yet been reached as to the value of comprehensive treatment for NPC. This study was designed to evaluate the epidemiological characteristics of NPC and their prognostic value, as well as the long-term efficacy of NPC treatment. PATIENTS AND

methodsA total of 248 patients, with different stages of NPC, were included in this study.

resultsThe 5-year overall survival (OS) rates for patients in stages I, II, III and IV were 90.48%, 76.71%, 76.89% and 33.87%, respectively (P=0.000), while the respective 5-year progression-free survival (PFS) rates were 85.15%, 72.36%, 63.88% and 26.26% (P=0.000). The respective 5-year OS rates, according to stage, for the group that received radiotherapy combined with chemotherapy and for the group that received radiotherapy only were as follows: stages I and II, 81.67% and 79.59% (P=0.753); stage III, 79.91% and 70.38% (P=0.143); stage IV, 35.22% and 0% (P=0.000). The respective 5-year PFS rates in these groups were as follows: stages I and II, 75.83% and 74.98% (P=0.814); stage III, 74.08% and 42.25% (P=0.027); stage IV, 27.31% and 0% (P=0.000).

conclusionsClinical staging appears to be the most important prognostic factor for NPC. As the stage number increases, both the 5-year OS and PFS significantly decrease. Adding chemotherapy to radiotherapy was not advantageous for patients with stage I or II NPC, however the addition of chemotherapy to radiotherapy significantly improved OS and PFS in patients with stage IV NPC. The addition of chemotherapy improved PFS, but not OS in patients with stage III NPC.

Indexed as

MacaoNasopharyngeal carcinoma (NPC)retrospective analysistreatment

Identifiers

PMID24826055
PMCPMC4000909
OpenAlexW2138055640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.